These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8970522)

  • 1. Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi-SPECT findings.
    Neumann DR; Esselstyn CB; Kim EY
    J Nucl Med; 1996 Dec; 37(12):2000-1. PubMed ID: 8970522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism.
    Neumann DR; Esselstyn CB; Maclntyre WJ; Go RT; Obuchowski NA; Chen EQ; Licata AA
    J Nucl Med; 1996 Nov; 37(11):1809-15. PubMed ID: 8917180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography.
    Arslan N; Rydzewski B
    Clin Nucl Med; 2002 Mar; 27(3):221-2. PubMed ID: 11852320
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
    Garcia R; Kim EE; Wong FC; Korkmaz M; Wong WH; Yang DJ; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1476-9. PubMed ID: 8790197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative imaging of parathyroid carcinoma by positron emission tomography.
    Neumann DR; Esselstyn CB; Siciliano D; MacIntyre WJ; Kohse LM; Licata AA
    Ann Otol Rhinol Laryngol; 1994 Sep; 103(9):741-5. PubMed ID: 8085739
    [No Abstract]   [Full Text] [Related]  

  • 6. Regional body FDG-PET in postoperative recurrent hyperparathyroidism.
    Neumann DR; Esselstyn CB; MacIntyre WJ; Chen EQ; Go RT; Licata AA
    J Comput Assist Tomogr; 1997; 21(1):25-8. PubMed ID: 9022764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of metastatic parathyroid carcinoma with Tc-99m sestamibi imaging.
    Al-Sobhi S; Ashari LH; Ingemansson S
    Clin Nucl Med; 1999 Jan; 24(1):21-3. PubMed ID: 9890488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent parathyroid carcinoma appearing as FDG negative but MIBI positive.
    Alabed YZ; Rakheja R; Novales-Diaz JA; Lisbona R
    Clin Nucl Med; 2014 Jul; 39(7):e362-4. PubMed ID: 24458176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism.
    Melon P; Luxen A; Hamoir E; Meurisse M
    Eur J Nucl Med; 1995 Jun; 22(6):556-8. PubMed ID: 7556303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technetium-99m-sestamibi SPECT localization of mediastinal parathyroid adenoma.
    Teigen EL; Kilgore EJ; Cowan RJ; Albertson DA
    J Nucl Med; 1996 Sep; 37(9):1535-7. PubMed ID: 8790213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distant subcutaneous recurrence of a parathyroid carcinoma: abnormal uptakes in the (99m)Tc-sestamibi scan and (18)F-FDG PET/CT imaging.
    Kim SS; Jeon YK; Lee SH; Kim BH; Kim SJ; Kim YK; Kim IJ
    Korean J Intern Med; 2014 May; 29(3):383-7. PubMed ID: 24851075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET.
    Neumann DR; Esselstyn CB; MacIntyre WJ; Chen EQ; Go RT; Kohse LM; Licata AA
    Radiology; 1994 Aug; 192(2):509-12. PubMed ID: 8029424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of double-phase 99mTc-sestamibi with 123I-99mTc-sestamibi subtraction SPECT in hyperparathyroidism.
    Neumann DR; Esselstyn CB; Go RT; Wong CO; Rice TW; Obuchowski NA
    AJR Am J Roentgenol; 1997 Dec; 169(6):1671-4. PubMed ID: 9393188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tc-99m pertechnetate/sestamibi imaging in a case of recurrent parathyroid carcinoma with metabolic bone disorder.
    Meng Z; Tan J; Zhang M; Dong F; Jia Q; Zhang F
    Clin Nucl Med; 2009 Jul; 34(7):479-82. PubMed ID: 19542965
    [No Abstract]   [Full Text] [Related]  

  • 15. Parathyroid detection in secondary hyperparathyroidism with 123I/99mTc-sestamibi subtraction single photon emission computed tomography.
    Neumann DR; Esselstyn CB; Madera A; Wong CO; Lieber M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3867-71. PubMed ID: 9814460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of an ectopic parathyroid adenoma by double-phase technetium-99m-sestamibi scintigraphy.
    Caravalho J; Balingit AG; Rivera-Rodríguez JE; Shriver CD; Koops MK
    J Nucl Med; 1995 Oct; 36(10):1840-2. PubMed ID: 7562052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synchronous Metastatic Breast Carcinoma and Parathyroid Adenoma on 18F-FDG PET/CT and 99mTc-Sestamibi Imaging.
    Singh H; Wale DJ; Wong KK; Gross MD; Viglianti BL
    Clin Nucl Med; 2019 Feb; 44(2):148-149. PubMed ID: 30418208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization and reoperation results for persistent and recurrent parathyroid carcinoma.
    Kebebew E; Arici C; Duh QY; Clark OH
    Arch Surg; 2001 Aug; 136(8):878-85. PubMed ID: 11485522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rest distribution of 99mTc-MIBI in patients with coronary artery disease assessed by SPECT: comparison with the distribution of [18F]FDG assessed by PET.
    Gang H; Lucignani G; Landoni C; Galli L; Vanoli G; Rossetti C; Paganelli G; Fazio F
    J Nucl Biol Med (1991); 1994 Dec; 38(4):540-4. PubMed ID: 7786915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease.
    vom Dahl J; Altehoefer C; Sheehan FH; Buechin P; Schulz G; Schwarz ER; Koch KC; Uebis R; Messmer BJ; Buell U; Hanrath P
    J Nucl Med; 1997 May; 38(5):742-8. PubMed ID: 9170439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.